According to a new report published by Allied Market Research, “Gene Therapy Market by Vector Type, Gene Type, and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026,” the size of the gene therapy market in 2018 will be 3 It was $93.39 million. It is estimated to reach $6,205.85 million by 2026 and will register a CAGR of 34.8% by 2019-2026.

Gene therapy is a promising treatment that can be applied to a wide range of diseases. Their purpose is not only to relieve symptoms, but to cure the cause of the disease radically. They can be effective against a wide range of previously untreated diseases, including blood disorders, eye disorders, neurodegenerative disorders, and some cancers. For example, an adeno-associated AAV2 vector injected intraretinally with a therapeutic gene (RPE65) improved vision in patients with Leber congenital amaurosis. Gene therapy can be applied in combination with cell products in an ex vivo therapeutic mode (eg Strimvelis) or directly administered in vitro (eg Glybera). Some vectors present clinically relevant options such as adenovirus (AV), adeno-associated virus (AAV), and lentivirus.

Click here to access our free sample report: www.alliedmarketresearch.com/request-sample/2841

Increasing funding for gene therapy R&D activities and raising awareness of gene therapy are key drivers of the growth of the gene therapy market. In addition, increased government support, ethical acceptance of gene therapy for cancer treatment, and rising cancer prevalence could boost the growth of the gene therapy market. However, the high costs associated with treatment and unwanted immune responses are expected to hinder the growth of the gene therapy market.

Among the vector types, non-viral vectors are advantageous in the global gene therapy market due to technological advances such as physicochemical approaches including substances such as lipids, naked DNA, chromosomes, plasmids, cationic polymers, and conjugates. The complex of these vectors has yielded positive results for these treatments during preclinical and clinical trials for the treatment of various diseases.

Of the genotypes, antigens make up the overall market, accounting for two-ninths of the global gene therapy market share in 2018. Among the applications, the Oncology Diseases segment makes the largest contribution to the growth of the gene therapy market. The availability of many gene therapy products that can be used to treat cancer and the large population base of patients. In addition, there are many gene therapies in clinical trials for cancer and cardiovascular disease.

In 2018, North America will be the largest contributor to total revenue and is expected to continue this gene therapy market trend during the forecast period. This is due to the high prevalence of cancer, high disposable income, and the large amount of funding needed for research and development activities related to gene therapy. However, in the Asia-Pacific region, rising cancer rates, increased government efforts to improve healthcare infrastructure, and increased healthcare spending are expected to produce the highest CAGR during the forecast period. I will.

Purchase Inquiries: www.alliedmarketresearch.com/purchase-enquiry/2841

Key findings in the gene therapy market:
• The non-viral vector segment is predicted to grow at the fastest CAGR of 34.6% during the analysis period.
• The Oncology Disease segment is expected to generate the highest revenues and continue to dominate the global gene therapy market in the future.
• Asia Pacific is projected to grow at a fasting CAGR during the forecast period.
• China is expected to grow fastest in the Asia Pacific region during the forecast period.
• Tumor suppressors are expected to grow fastest during the forecast period.

The report shows Adaptimmune Therapeutics Plc, a leading company operating in the global gene therapy market industry. , Anchiano Therapeutics Ltd., Achieve Life Sciences, Inc., Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetics provides comprehensive analysis of Technologies Corporation, Arbutus Biopharma Corporation, Audentes Therapeutics, Inc., AveXis, Inc., Bluebird Bio, Inc., Celgene Corporation, CRISPR Therapeutics AG, Editas Medicine, Inc., Editas Medicine, Inc., GlaxoSmithKline Plc. , Intellia Therapeutics, Inc., Merck & Co., Inc., Novartis AG, REGENXBIO Inc., Spark Therapeutics, Inc., Sangamo Therapeutics, Inc., Uniqure NV, Voyager Therapeutics, Inc.

Other prominent players in the value chain (company not listed in the report) include Amgen, Epeius Biotechnologies, Sanofi, Juno Therapeutics and Advantagene.



Source link